Related Experiment Video

Updated: May 24, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers

Anurag Singh1, Michael F Sweeney, Min Yu

  • 1Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA.

Cell
|February 21, 2012
PubMed

Insights

Targeting TAK1 kinase (MAP3K7) offers a new therapeutic strategy for KRAS-mutant colon cancers. This kinase is essential for tumor cell survival by suppressing Wnt signaling, presenting a potential treatment avenue.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • KRAS mutations are common in colon cancer, but not all KRAS-mutant cells depend on KRAS signaling for survival.
  • Identifying specific dependencies in these resistant cancer subsets is crucial for developing effective therapies.

Purpose of the Study:

  • To identify kinases essential for the survival of KRAS-dependent colon cancer cells.
  • To investigate the role of TAK1 kinase in KRAS-mutant colon cancer survival and Wnt signaling.

Main Methods:

  • Kinase screening to identify survival-promoting kinases in KRAS-dependent colon cancer cells.
  • RNA interference (RNAi) and pharmacologic inhibition to deplete or block TAK1 activity.
  • Analysis of Wnt signaling activation and apoptosis induction.
  • Assessment of BMP signaling pathways and their link to TAK1 activation.
  • Evaluation of a "TAK1 dependency signature" in primary human colon cancer samples.

Main Results:

  • TAK1 kinase (MAP3K7) was identified as essential for the viability of KRAS-dependent colon cancer cells.
  • Inhibition of TAK1 induced apoptosis by suppressing hyperactivated Wnt signaling.
  • KRAS signaling in APC mutant/KRAS-dependent cells stimulates BMP-7 secretion, leading to TAK1 activation and enhanced Wnt signaling.
  • A "TAK1 dependency signature" was enriched in human colon cancers with both APC and KRAS mutations.

Conclusions:

  • TAK1 kinase is a critical mediator of survival in a subset of KRAS-mutant colon cancers.
  • TAK1 inhibition represents a potential therapeutic strategy for treatment-refractory colon cancers with aberrant KRAS and Wnt pathway activation.
  • The findings suggest clinical utility in stratifying patient populations based on specific mutations.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...